These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38274823)

  • 41. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Monk BJ; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Hurtado de Mendoza MO; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Martin Nguyen A; Monberg MJ; Colombo N; Lorusso D
    Lancet Oncol; 2023 Apr; 24(4):392-402. PubMed ID: 36878237
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.
    Huang M; Fasching P; Haiderali A; Pan W; Gray E; Zhou ZY; Hu P; Chaudhuri M; Bailly De Tilleghem CL; Cappoen N; O'Shaughnessy J
    Immunotherapy; 2022 Sep; 14(13):1027-1041. PubMed ID: 35796042
    [No Abstract]   [Full Text] [Related]  

  • 43. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
    Li F; Chen Y; Xiao D; Jiang S; Yang Y
    Adv Ther; 2024 Apr; 41(4):1436-1449. PubMed ID: 38356107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
    Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
    J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China.
    Lin YT; Zhou CC; Xu K; Zhang MD; Li X
    Ther Adv Med Oncol; 2023; 15():17588359231213621. PubMed ID: 38028139
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach.
    Hui W; Song R; Tao H; Gao Z; Zhu M; Zhang M; Wu H; Gong D; Zhang X; Cai Y
    BMC Cancer; 2023 May; 23(1):442. PubMed ID: 37189081
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.
    Liu T; Liu S; Guan S; Tai Y; Jin Y; Dong M
    J Chemother; 2023 Dec; 35(8):745-752. PubMed ID: 36591729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
    PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
    Monk BJ; Colombo N; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Keefe SM; Lorusso D;
    J Clin Oncol; 2023 Dec; 41(36):5505-5511. PubMed ID: 37910822
    [No Abstract]   [Full Text] [Related]  

  • 53. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
    Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
    J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
    Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
    Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer.
    Georgieva M; da Silveira Nogueira Lima JP; Aguiar P; de Lima Lopes G; Haaland B
    Lung Cancer; 2018 Oct; 124():248-254. PubMed ID: 30268469
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China.
    Zheng Z; Fang L; Cai H
    BMC Cancer; 2023 Sep; 23(1):823. PubMed ID: 37667230
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis.
    Wu B; Lu S
    Transl Lung Cancer Res; 2020 Oct; 9(5):1770-1784. PubMed ID: 33209600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
    Liang X; Chen X; Li H; Liu X; Li Y
    Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.